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Abstract
Group A Streptococcus (GAS) is a human specific pathogen capable of causing both mild infections and severe invasive
disease. We and others have shown that GAS is able to form biofilms during infection. That is to say, they form a three-
dimensional, surface attached structure consisting of bacteria and a multi-component extracellular matrix. The mechanisms
involved in regulation and dispersal of these GAS structures are still unclear. Recently we have reported that in the absence
of the transcriptional regulator Srv in the MGAS5005 background, the cysteine protease SpeB is constitutively produced,
leading to increased tissue damage and decreased biofilm formation during a subcutaneous infection in a mouse model.
This was interesting because MGAS5005 has a naturally occurring mutation that inactivates the sensor kinase domain of the
two component regulatory system CovRS. Others have previously shown that strains lacking covS are associated with
decreased SpeB production due to CovR repression of speB expression. Thus, our results suggest the inactivation of srv can
bypass CovR repression and lead to constitutive SpeB production. We hypothesized that Srv control of SpeB production
may be a mechanism to regulate biofilm dispersal and provide a mechanism by which mild infection can transition to
severe disease through biofilm dispersal. The question remained however, is this mechanism conserved among GAS strains
or restricted to the unique genetic makeup of MGAS5005. Here we show that Srv mediated control of SpeB and biofilm
dispersal is conserved in the invasive clinical isolates RGAS053 (serotype M1) and MGAS315 (serotype M3), both of which
have covS intact. This work provides additional evidence that Srv regulated control of SpeB may mediate biofilm formation
and dispersal in diverse strain backgrounds.
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Introduction
Group A Streptococcus (GAS) is responsible for infections that
span a broad spectrum of clinical severity, from mild to severe [1].
In the United States alone, it has been estimated that there are
15,000 cases of invasive GAS infections annually, including cases
of necrotizing fasciitis and toxic shock syndrome, with a mortality
rate of ,10% [2,3]. Since the reemergence of invasive disease in
the 1980’s, serotype M1 and M3 strains of GAS have been most
commonly associated with causing severe invasive infections
[3,4,5].
CovRS (also known as CsrR/S) is the most studied of the 13
known two-component signal transduction systems (TCS) in GAS,
and primarily functions as a negative regulatory system, with
regulatory targets including numerous virulence factors
[6,7,8,9,10,11,12,13]. The sensor kinase domain, CovS, has been
hypothesized to function as both a kinase and phosphatase of the
response regulator CovR [6,14,15,16]. However, CovR is able to
function in the absence of CovS, and it has been predicted that
acetyl phosphate may also serve to activate CovR [17,18,19,20].
Phosphorylation of CovR increases DNA binding affinity for
promoter regions of target genes [21,22,23,24]. Recently, it has
been observed that spontaneous mutations in CovRS have been
associated with strains isolated from invasive disease in both
clinical samples and samples isolated during in vivo infection
models [19,25,26,27,28,29]. Most commonly, covRS mutations
that arise result in truncation and subsequent inactivation of covS,
leaving a functional covR gene intact, as observed in the invasive
clinical isolate MGAS5005 [19,27,29].
One of the GAS virulence factors that is repressed by CovRS is
the extracellular cysteine protease, SpeB [8,26]. SpeB cleaves host
proteins resulting in increased damage at the site of a localized
infection, such as fibronectin, vitronectin, and pro-matrix
metalloproteases [30,31,32,33]. While SpeB may promote local-
ized tissue damage, it also degrades GAS virulence factors that are
involved in promoting systemic disease, including M protein,
streptokinase, and streptococcal pyrogenic exotoxin A (SpeA)
[25,30]. This suggests high SpeB levels may be beneficial for
increasing virulence during a localized infection, but are
potentially detrimental during invasive infections. GAS strains
lacking covS, such as MGAS5005, continue to have speB repressed
by CovR [19,28,29]. In contrast, strains lacking covR produce
more SpeB than wild-type strains, suggesting that CovS functions
to alleviate CovR repression of speB [19,28,29]. Animal passage
strains that acquired a covS mutation showed a SpeB-low
phenotype, were better able to survive systemically and were
more virulent compared to wild-type covS, SpeB-high counterparts
[12,19,25,27,28].
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produced following allelic replacement of the streptococcal
regulator of virulence (Srv) in MGAS5005, a M1T1 GAS clinical
isolate that produces low levels of SpeB during late exponential
and early stationary phases of planktonic growth [34,35,36]. We
have also demonstrated that constitutive SpeB production by
MGAS5005Dsrv results in decreased in vitro biofilm formation,
and biofilm formation can be restored following chemical or
genetic inactivation of speB/SpeB [37,38]. Generally, a bacterial
biofilm has been defined as a bacterial sessile community encased
in an extracellular matrix that is attached to a substratum or
interface [39]. The specific components of a GAS biofilm still
remain to be defined, however, our lab and others have used the
presence of microcolonies, a non-random aggregation of GAS
within an active infection, as indication of biofilm formation in
vivo [40,41,42,43]. In a chinchilla model of otitis media,
MGAS5005Dsrv is dispersed throughout the structures isolated
from the middle ear cavity, whereas MGAS5005 and
MGAS5005DsrvDspeB are readily visible in microcolonies [43].
MGAS5005Dsrv is also dispersed throughout lesions excised from
murine subcutaneous infections, whereas MGAS5005 begins to
aggregate by 3 days post-infection (dpi) and microcolonies are
present by 8 dpi [42]. Decreased biofilm formation by
MGAS5005Dsrv in a murine subcutaneous infection model
correlated with increased tissue damage at the site of infection
[42]. The MGAS5005 phenotype was restored in
MGAS5005Dsrv following both chemical inhibition of SpeB with
E64, as well as by allelic replacement of speB in the
MGAS5005Dsrv background [42].
One question that we have consistently received from colleagues
is that if MGAS5005 has a mutated covS, are the results that we
observed with MGAS5005Dsrv the same in strains that possess an
intact covS? As mentioned, inactivation of srv in the MGAS5005
background surpassed CovR regulation of SpeB resulting in
constitutive production of the cysteine protease. In this study, we
wanted to test the hypothesis that Srv regulation of SpeB
production was conserved in other invasive clinical isolates, and
that this was a covS-independent effect. We utilized the invasive
clinical isolates RGAS053 (a serotype M1 strain) and MGAS315
(serotype M3), both of which possess a functional covS gene, to
demonstrate that Srv regulation of SpeB and biofilm formation/
dispersal is conserved among the strains examined.
Results
Inactivation of srv in CovS+ clinical isolates resulted in
decreased biofilm formation
Our previous studies illustrated that there is a significant
decrease in biofilm formation following allelic replacement of srv in
MGAS5005, a clinical isolate lacking a functional covS
[37,38,42,43]. To examine if the effect of decreased biofilm
formation was specific to MGAS5005, either due to M-type or the
lack of covS, we examined two additional clinical isolates of GAS,
MGAS315 and RGAS053. Sequencing and real time RT-PCR
analysis confirmed that both strains possess a full-length,
functional covS gene (data not shown). MGAS315 is a M3 serotype
strain isolated from a case of GAS toxic shock syndrome in the late
1980’s and has been well characterized [4,44,45,46,47]. RGAS053
is a M1 serotype strain isolated from a case of invasive GAS
disease obtained from Dr. Gary Doern [48]. The isogenic mutants
MGAS315Dsrv and RGAS053Dsrv were generated by allelic
replacement as previously described [46,49,50]. Sequencing
verified that replacements were in frame and transcription of
neighboring genes was unaffected (data not shown). We first
examined the ability of these strains to form in vitro biofilms over
time using a CV staining assay. At all time points, RGAS053
showed significantly increased levels of biofilm formation com-
pared to RGAS053Dsrv (Figure 1A). MGAS315 established
minimal levels of biofilm formation over the course of observation,
however, it was still significantly increased compared to
MGAS315Dsrv biofilm formation (Figure 1B). For comparison,
as we have previously shown, MGAS5005 was able to establish a
robust biofilm, whereas MGAS5005Dsrv produced significantly
less biofilm (Figure 1C).
Figure 1. Inactivation of srv in RGAS053 and MGAS315 resulted
in decreased biofilm formation. Log-phase cultures of (A) RGAS053
(solid line) and RGAS053Dsrv (dashed line), (B) MGAS315 (solid line) and
MGAS315Dsrv (dashed line), or (C) MGAS5005 (solid line) MGAS5005Dsrv
(dashed line) were grown in 6-well plates and adherence was measured
over a course of 48h using a CV staining assay. All Dsrv mutants were
significantly reduced in forming biofilms compared to wild-type strains.
Each reported value for the CV assay is an average of 6 replicates and is
adjusted by the dilution factor required to obtain a spectrophometric
reading (OD600 nm)( * p#0.01, **p#0.001, ***p#.0001; unpaired t-test).
doi:10.1371/journal.pone.0028640.g001
Srv Regulation Is Conserved in GAS
PLoS ONE | www.plosone.org 2 December 2011 | Volume 6 | Issue 12 | e28640Biovolume and average thickness are significantly
decreased in Dsrv in vitro static biofilms
To better quantify the structure of in vitro GAS biofilms, images
captured using CLSM of Live/Dead stained biofilms were
analyzed with COMSTAT. The parameters examined by
COMSTAT were biomass, which indicates the overall volume
of the biofilm, and average thickness of the biofilms [51]. While
the average thickness of RGAS053 was statistically higher than
RGAS053Dsrv only at 48h, the total biomass of RGAS053 was
significantly increased at all time points observed (Figure 2A).
MGAS315 formed thicker biofilms with increased biomass
compared to MGAS315Dsrv at all time points (Figure 2B).
MGAS5005 also formed biofilms that had significantly increased
average thickness and biomass than MGAS5005Dsrv over the
course of the experiment (Figure 2C).
DNase and proteinase inhibit/disrupt RGAS053 biofilm
formation, but only proteinase inhibits/disrupts
MGAS315 biofilm formation
DNase I or proteinase K were added either at the time of
biofilm seeding or to an established 24 h biofilm to examine the
effect of enzyme addition on inhibition or disruption of biofilm
formation, respectively. Addition of DNase I to RGAS053 and
RGAS053Dsrv both inhibited and disrupted biofilm formation
(Figure 3A). The higher concentration of proteinase K showed
greater inhibition when added at the time of seeding to either
RGAS053 or RGAS053Dsrv biofilms, but both concentrations
significantly inhibited biofilm formation (Figure 3A). Proteinase K
also disrupted an already formed biofilm for both strains, however,
there was no difference observed between the concentrations used
(Figure 3A). DNase I had no effect on inhibition or disruption of
MGAS315 or MGAS315Dsrv biofilms (Figure 3B). MGAS315
biofilm formation was both inhibited and disrupted by proteinase
K (Figure 3B). MGAS315Dsrv was only inhibited by 1 mg/ml
proteinase K, and neither enzyme produced any effect on biofilm
disruption (Figure 3B). Comparable to what we have previously
shown, MGAS5005 biofilm formation was both inhibited and
disrupted by the addition of DNase I or proteinase K (Figure 3C)
[37]. MGAS5005 biofilms showed both increased inhibition and
disruption when a higher concentration of proteinase K is added
(Figure 3C). MGAS5005Dsrv biofilm formation was even further
decreased following the addition of DNase I or proteinase K at the
time of seeding and after 24h (Figure 3C).
Higher levels of active SpeB detected in Dsrv in vitro
biofilm supernatant
We have previously shown that SpeB is present in the
supernatant of 24 h MGAS5005Dsrv in vitro biofilms, but is not
detectable in MGAS5005 biofilms using a western immunoblot
assay [37]. To examine SpeB production over the course of in vitro
biofilm formation, supernatant was collected every 12 h over 48 h.
Samples were probed using Western immunoblot analysis with an
anti-SpeB primary antibody, and purified SpeB antigen was used
as a positive control on each blot. The mean pixel intensity (MPI)
was determined for active SpeB (28 kDa) bands using Carestream
Molecular Imaging Software. Active SpeB was detected in
RGAS053 biofilm supernant, and increased over 48 h. Higher
levels of SpeB were present in supernatant collected from
RGAS053Dsrv biofilms, and these levels also increased at later
time points (Figure 4A). Low levels of active SpeB were detected in
both MGAS315 and MGAS315Dsrv over 48 h, however MPI
were higher and increased over time for MGAS315Dsrv
(Figure 4B). Consistent with what has been observed previously
[37], no active SpeB was detected in MGAS5005 supernatant, but
SpeB was detected in MGAS5005Dsrv biofilm supernatant
(Figure 4C).
Chemical inhibition of SpeB restores Dsrv in vitro biofilm
formation to wild-type levels
E64 is a commercially available cysteine protease inhibitor that
we have previously shown to inhibit SpeB and increase biofilm
formation both in vitro and in vivo [37,42]. To examine the effect of
SpeB inhibition on biofilm formation, E64 was added at the time
of seeding of RGAS053, MGAS315, and MGAS5005 wild-type
and Dsrv 24 h biofilms. Addition of E64 to RGAS053Dsrv restored
biofilm formation to wild-type levels, and E64 was also able to
significantly increase biofilm formation of RGAS053 (Figure 5).
MGAS315Dsrv biofilms were significantly increased following
addition of E64, however, there was no effect of E64 on
Figure 2. COMSTAT analysis of MGAS315 and MGAS315Dsrv in
vitro static biofilms. Static biofilms were stained with a LIVE/DEAD
reagent and imaged using CLSM for COMSTAT analysis. 12 individual
fields of view were used for each strain from 12, 24 and 48h biofilms. (A)
Total biomass of RGAS053 was significantly greater than RGAS0535Dsrv
at all timepoints, and formed significantly thicker biofilms at 48 h. (B, C)
Total biomass and average thickness were significantly increased in
wild-type strains compared to Dsrv strains for both MGAS315 and
MGAS5005, respectively. (**p#.01, ***p#0.001; unpaired t-test).
doi:10.1371/journal.pone.0028640.g002
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previously shown [37], MGAS5005Dsrv biofilm formation was
restored when E64 was added at the time of seeding, and no effect
from E64 was seen on MGAS5005 biofilms (Figure 5).
Allelic replacement of srv in RGAS053 and MGAS315 lead
to increased lesion size in a murine subcutaneous
infection model
Based on our in vitro data, and what we have previously observed
with MGAS5005, we hypothesized that lesions would be larger in
mice infected with RGAS053Dsrv and MGAS315Dsrv when
compared to infections with wild-type strains [42]. To assess the
loss of srv in RGAS053 and MGAS315 during an in vivo infection
model, groups of 10 mice were inoculated with ,2610
8 CFU of
either RGAS053, RGAS0535Dsrv, MGAS315 or MGAS315Dsrv.
The area of the lesion and average percentage of weight loss were
monitored and recorded for 8 dpi. Lesions and the underlying
abscess were surgically excised, homogenized, and the bacteria
were enumerated to determine CFU present (n=3 mice/strain).
No difference in bacterial load was observed at 1, 3, and 8 dpi
(data not shown). This matches what we have previously observed
[42]. Overall, animals infected with either RGAS053Dsrv or
MGAS315Dsrv developed larger lesions over the course of the
infection compared to mice infected with the parental strains
(Figure 6A and B).
RGAS053 formed microcolonies (biofilms) in vivo, but no
microcolonies were observed in MGAS315 infected tissue
In vitro biofilm formation showed that only RGAS053 formed
robustbiofilms, while RGAS053Dsrv,MGAS315, and MGAS315Dsrv
producedminimallevels of adherence. Based onthis, wehypothesized
Figure 3. Enzymic inhibition and disruption of in vitro wild-type
and Dsrv biofilms. DNase I (200 mg/ml) or proteinase K (0.1 or 1 mg/ml)
were added to in vitro biofilms at the time of seeding (inhibition) or after
24hgrowth(disruption).(A)RGAS053andRGAS053Dsrvbiofilmformation
were both disrupted and inhibited by DNase I and proteinase K. (B)
MGAS315 and MGAS315Dsrv were not inhibited or disrupted by DNase I.
Proteinase K inhibited and disrupted MGAS315 biofilm formation.
MGAS315Dsrv biofilm formation was inhibited by 1 mg/ml proteinase K,
but biofilm disruption was not observed with either concentration of
proteinase K. (C) Proteinase K and DNase I both inhibited and disrupted
MGAS5005andMGAS5005Dsrv biofilm formation. Eachreportedvaluefor
the CV assay is an average of 6 replicates and is adjusted by the dilution
factor required to obtain a spectrophometric reading (OD600 nm)( * p#.05,
**p#.01, ***p#0.001; unpaired t-test).
doi:10.1371/journal.pone.0028640.g003
Figure 4. Detection of active SpeB in GAS biofilms. Western
immunoblot analysis was used to detect the presence of SpeB in
supernatants collected from (A) RGAS053, (B) MGAS315 (C) MGAS5005
wild-type and Dsrv static biofilms at 12, 24, 36 and 48 h post seeding.
The Mean Pixel Intensity (MPI) of active SpeB (28 kDa) was measured
with Carestream Image Software. MPI of SpeB for both RGAS053 and
MGAS315 increased over 48 h, and SpeB production was increased in
Dsrv mutants compared to wild-type for both strains. Low/no SpeB was
detected in MGAS5005 biofilms, but was detected in MGAS5005Dsrv
biofilms at all time points.
doi:10.1371/journal.pone.0028640.g004
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infected tissue. Microcolony formation has previously been used as
evidence of biofilm formation in vivo [33,40,41,42,43]. Lesion tissue
from each strain was excised at 8 dpi (n=3 mice/strain), and 10 mm
sections of each were subjected to Gram-staining. Representative
images from the same field of view are shown at 606 and 1006
magnification (Figure 7). RGAS053 infected samples contained
abundant microcolonies of adherent GAS throughout the site of
infection (Figure 7). RGAS053Dsrv infected samples contained
randomly dispersed GAS throughout the infected tissue, and
microcolonies were largely absent (Figure 7). Dispersed GAS was
present, and microcolony formation was not observed in lesion tissue
excised from either MGAS315 or MGAS315Dsrv infected samples
(Figure 7).
Use of the cysteine protease inhibitor E64 reduced lesion
size following RGAS053Dsrv infection but increased
lesion size following MGAS315Dsrv infection
Previously, we have demonstrated that daily treatment of
MGAS5005Dsrv subcutaneous infections with E64 significantly
reduced lesion development to wild-type levels presumably due to
the inhibition of SpeB [42]. Since E64 increased RGAS053Dsrv in
vitro biofilm formation to wild-type levels, we hypothesized that we
would observe a similar effect on lesion development as we have
previously observed with E64 treatment of MGAS5005Dsrv
infections. Decreased levels of SpeB in MGAS315 infections
results in more virulent infections due to a combination of
virulence factors that are unique to this strain, including
streptodornase (Sdn) and phospholipase (Sla), no longer being
degraded by SpeB [4,13,52,53]. Based on this, we hypothesized
that addition of E64 treatment would increase virulence and lesion
formation following subcutaneous infection with MGAS315 and
MGAS315Dsrv. The infecting dose (,2610
8 CFU) of MGAS315,
MGAS315Dsrv, RGAS053 or RGAS053Dsrv was resuspended in
E64 (0.1 ml), and E64 (0.1 mL) was injected directly into the
abscess each day following infection (n=3 mice/strain). The area
of the lesion and average percentage of weight loss were monitored
and recorded for 8 dpi. Daily subcutaneous injection of E64-
DPBS (0.1 ml) only showed no visible effect compared to
untreated, uninfected mice (data not shown). No difference in
percentage of weight loss was observed (data not shown). Lesions
and the underlying abscess were surgically excised, homogenized,
and bacteria enumerated to determine CFU present (n=3 mice/
strain). No difference in bacterial load was observed at 1, 3, and
8 dpi (data not shown). No significant effect of daily E64 treatment
on lesion development was observed following RGAS053 infection
(Figure 8A). While not significant, a trend was observed where
lesion formation was decreased following E64 treatment of
RGAS053Dsrv compared to untreated RGAS053Dsrv (Figure 8B).
Following MGAS315 infection, a trend was also observed where
lesion area increased in mice that received E64 treatments
(Figure 8C). Treatment of MGAS315Dsrv with E64 daily resulted
in larger lesion formation compared to untreated infections
(Figure 8D).
Discussion
Previously, we have shown that the loss of the stand-alone
response regulator Srv in MGAS5005 resulted in significant
reduction of in vitro biofilm formation in both static and flow
biofilm assays [37,38]. Furthermore, MGAS5005Dsrv exhibited
reduced biofilm formation in vivo in both a chinchilla model of
otitis media and a murine soft tissue model [42,43]. The loss of
biofilm formation by MGAS5005Dsrv was attributed to constitu-
tive production of the cysteine protease SpeB, as biofilm formation
was restored through either chemical inhibition of SpeB or allelic
replacement of speB in the MGAS5005Dsrv background in both in
vitro and in vivo biofilm models [37,38,42,43]. One long term goal
of our laboratory is to understand the role of the GAS biofilm in
disease. Our recent work in both chinchillas and mice have
provided evidence that biofilm formation is not required for
infection at two distinct host sites (skin and middle ear), or at least
not required given the means of inoculation used. However, our
growing data also suggests that most strains would naturally form a
biofilm upon infection. We envision a model where biofilm
formation is used for colonization of a host site and protection
from the innate immune response. Coordinate regulation of speB
by Srv (and perhaps other regulators) would allow for the
controlled production of SpeB that would facilitate dispersal of
some portion of GAS from the biofilm to achieve spread to
another host site or susceptible host. Under this model, loss of
regulation of this system would lead to severe disease. One
weakness of our current model is that, to this point, our model is
based on observations obtained using only MGAS5005. Our data
are complicated by the fact that MGAS5005, as discussed in the
Introduction, has a mutation in covS rendering CovS non-
functional [19,27,29]. It should be noted that this does not
invalidate MGAS5005 as a strain worthy of study. MGAS5005
was isolated from a patient suffering from invasive disease. In fact,
several recent studies have shown evidence of GAS with covS non-
functional mutations isolated from in vivo systemic infections,
suggesting that covS mutants posses a selective advantage during
invasive infections [7,12,13,15,19,27,54,55]. However, in order to
further test the validity of our model, we chose to examine the
biofilm formation and virulence of the srv isogenic mutants of two
Figure 5. Addition of E64 restores Dsrv in vitro biofilm
formation to wild-type levels. E64 (100 mM) was added to each
well at the time of seeding of wild-type and Dsrv RGAS053, MGAS315,
and MGAS5005 24 h biofilms. E64 restored biofilm formation of all Dsrv
strains to wild-type levels. RGAS053 biofilm formation was increased
compared to untreated RGAS053. Each reported value for the CV assay
is an average of 6 replicates and is adjusted by the dilution factor
required to obtain a spectrophometric reading (OD600 nm)( * p#.01,
**p#0.001, ***p#.0001; unpaired t-test).
doi:10.1371/journal.pone.0028640.g005
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alleles. Our results provide several new insights into GAS
pathogenesis.
First, allelic replacement of srv resulted in decreased biofilm
formation in each of the strains examined. The strains utilized in
this study are interesting because they demonstrate a wide range of
biofilm phenotypes. MGAS5005 is clearly a robust producer of
biofilm which is heavily dependent on the control of SpeB by Srv.
In the middle we have RGAS053, and intermediate producer of
biofilm. When srv is lost, biofilm formation by RGAS053 is
significantly reduced and detectable levels of SpeB are increased.
Unlike MGAS5005, SpeB is detected in RGAS053 biofilm
supernatants. We take this as further support for our model. In
our model, control of SpeB production is not all or nothing, but
rather we envision controlled production of SpeB to allow
dispersal of portions of the biofilm to allow for dissemination to
other hosts or host sites. At the same time, this controlled
production would allow for maturation of existing biofilms to a
level appropriate for the environmental conditions. Loss of srv in
RGAS053 did result in larger lesion development, and loss of
Figure 6. Allelic replacement of srv lead to increased lesion size in a murine subcutaneous infection model. Groups of 10 mice
(Crl:SKH1-hrBR) were challenged subcutaneously with ,2.0610
8 CFU (0.1 ml) of either MGAS315, MGAS315Dsrv, RGAS053 or RGAS053Dsrv. The area
of the lesion formed (mm
2) was measured with a caliper daily and the percentage of weight lost was monitored for 8 dpi. (A) A trend of increased
lesion area formed by RGAS053Dsrv (open circles) than those formed by RGAS053 (closed circles) was observed. Over the course of the infection,
there was no difference in weight loss except at 8 dpi. (B) A trend of larger lesions was also observed for MGAS315Dsrv infected mice (open triangles)
when compared to MGAS315 infected mice (closed triangles). Beginning at 5 dpi, mice infected with MGAS315 (closed triangles) had increased
weight loss compared to those infected with MGAS315Dsrv (open triangles) (*p#0.05, **p#0.01, ***p#.001; unpaired t-test).
doi:10.1371/journal.pone.0028640.g006
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that complete dispersal of the biofilm and increased production of
SpeB lead to more severe disease.
At the other end of the spectrum we have MGAS315, a strain
producing biofilm that may be arguably at the low end of
detection. However, loss of srv still resulted in significantly
measurable decreases in biofilm formation for this strain and the
addition of DNaseI or proteinase K was able to inhibit or disrupt
the structures in MGAS315 as well. MGAS315 was isolated from a
case of invasive streptococcal toxic shock syndrome [4] and it has
been hypothesized that the lack of SpeB production by MGAS315
prevents the degradation of the secreted virulence factors Sdn and
Sla that are associated with the increased severity of invasive
disease characteristic of this strain [13,52,53]. Under static growth
conditions, we are able to detect SpeB production by MGAS315
suggesting that this type of growth may induce SpeB production
by some strains. Loss of srv resulted in increased detection of SpeB
in MGAS315Dsrv and an increase in lesion size in the murine
model. Strikingly, inhibition of SpeB by E64 in MGAS315Dsrv
infected animals lead to even larger lesion formation. While it is
possible that E64 is inhibiting some host component(s) that may be
contributing to this effect, it further supports the hypothesis that
the virulence of MGAS315 is increased in the absence of SpeB.
Taken together, our data provide further support for a model in
which Srv regulated control of SpeB production mediates GAS
biofilm formation and dispersal. While this system appears
conserved among the strains examined, it highlights the diversity
within GAS strains and the effect this diversity has on virulence.
The work also points to a need to examine this system in strains
other than those isolated from cases of severe disease, as biofilms,
based on our observations, are likely less important in cases of
severe GAS disease. That said, loss of the ability to regulate biofilm
dispersal may be one mechanism by which a strain may transition
from mild to severe disease. Finally, the data suggest that Srv likely
interacts with one or more other regulators in its control of SpeB.
This mechanism is a focus of our ongoing investigation.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Animal Care and Usage Committee
of the Wake Forest University School of Medicine (Animal
Welfare Assurance #A3391-01). All procedures were performed
under isoflurane anesthesia, and all efforts were made to minimize
suffering.
Bacterial strains and growth conditions
The isogenic mutants MGAS5005Dsrv, MGAS315Dsrv and
RGAS053Dsrv, were generated by allelic replacement as previ-
ously described [46,49,50]. For all assays, overnight cultures
grown in Todd Hewitt broth (Becton-Dickinson) supplemented
with 2% yeast extract (THY) (Fisher Scientific) at 37uC, 5% CO2
were diluted into fresh THY and allowed to reach logarithmic
phase.
In vitro crystal violet (CV) adherence assay
Overnight cultures grown in Todd Hewitt broth (Becton-
Dickinson) supplemented with 2% yeast extract (THY) (Fisher
Scientific) at 37uC, 5% CO2 were diluted into fresh THY and
allowed to reach logarithmic phase (OD600=0.5). Biofilm
formation was determined using CV staining as previously
described [37]. Briefly, six-well tissue culture treated polystyrene
plates (Corning) were seeded with 3 ml of culture per well.
Surface-attached bacteria were stained with 0.1 % CV (Sigma-
Aldrich) dissolved in dH2O. The CV was solubilized with 1 ml
ethanol per well and an OD600 reading was recorded for each
sample. A time course analysis was performed and bacterial
adherence was measured at 0.5 h, 1 h and then every 6 h after
seeding for 48 h.
Live/Dead staining of static biofilms and CLSM analysis
Lab-tek II chambered #1.5 German borosilicate coverglass
wells (Nunc) were coated in Poly-L-Lysine (Sigma), seeded with
logarithmic phase cultures (3 ml), and incubated for 12, 24 or 48 h
at 37uC, 5% CO2. Supernatant was removed and biofilms were
washed once with 16 Dulbecco’s Phosphate Buffered Saline
(DPBS). Biofilms were stained with a Live/Dead BacLight viability
kit (Invitrogen) before samples were visualized using a Nikon
Eclipse Ti CLSM and Nikon EZ-C1 v. 3.80 software. Twelve
image stacks of Z-series, each representing a different field of view,
were collected for each strain at each time point. The Z-slice
images were exported into MATLAB (version 5.1) using NIS
Elements Imaging Software, and COMSTAT analysis was
performed using the Image Processing Toolbox to calculate total
biomass (mm
3/mm
2) and average thickness (mm) as previously
described [51,56].
Figure 7. Gram-staining of lesion tissue sections revealed the
presence of RGAS053 microcolonies (biofilms). 10 mm sections of
lesion tissue excised at 8 dpi were subjected to Gram-staining. RGAS053
infected samples contained microcolonies of adherent GAS (arrows).
RGAS053Dsrv infected samples contained randomly dispersed GAS
throughout the field of view and microcolonies were largely absent.
Microcolony formation was not observed in lesion tissue excised from
either MGAS315 or MGAS315Dsrv infected samples. Representative
images from the same field of view are shown at 606 and 1006
magnification.
doi:10.1371/journal.pone.0028640.g007
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formation
Enzymic inhibition/disruption assays were based on those
previously described [37]. Enzymes were added individually to
wells at a final concentration of: 200 mg/ml DNase I, 0.1 mg/ml
proteinase K, or 1 mg/ml proteinase K. Mock treatment used
addition of sterile dH2O instead of enzyme. Biofilm inhibition was
assessed by adding enzymes at the time of seeding and incubating
biofilms for 24 h. Biofilm disruption was measured by addition of
enzymes to a 24 h established biofilm, followed by a 1 h
Figure 8. E64 treatment reduced lesion size in RGAS053Dsrv infected mice but increased lesion size in MGAS315Dsrv infected mice.
The infecting dose (,2610
8 CFU) of MGAS315, MGAS315Dsrv, RGAS053 or RGAS053Dsrv was resuspended in 333 mM E64 (0.1 ml), and 333 mM E64
(0.1 ml) was injected directly into the abscess each day following infection (n=3 mice/strain). Lesion development (mm
2) and weight were
monitored over 8 days. Representative images of subcutaneous infections are shown from 1, 3, and 8 dpi for each strain. (A) No difference was
observed between E64 treated (open circles) and untreated (closed circles) RGAS053 infections over 8 dpi. (B) A trend was observed where lesion
formation was decreased following E64 treatment of RGAS053Dsrv (open circles) compared to inoculation with RGAS053Dsrv alone (closed circles).
(C) No difference was observed between E64 treated (open triangles) and untreated (closed triangles) MGAS315 infections over 8 dpi. (D) Lesion
formation was significantly increased following E64 treatment of MGAS315Dsrv (open triangles) compared to untreated infections (closed triangles)
(*p#0.05; unpaired t-test).
doi:10.1371/journal.pone.0028640.g008
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stained as described above.
Western immunoblot analysis
Cell-free supernatant was recovered from static biofilms at 12,
24, 36 and 48 h post seeding and analyzed for SpeB production
using a standard western immunoblot protocol. Briefly, samples
(30 ml) were analyzed by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and immunoblot. Purified active
SpeB (Toxin Technology, Inc.) served as a positive control.
Membranes were blocked in 3% skim milk (Difco) TBST
overnight at 4uC, incubated with rabbit anti-SpeB (1:5000) (Toxin
Technology, Inc.) primary antibody, and then incubated with goat
anti-rabbit HRP-conjugated secondary antibody (1:8000) (Pierce).
Incubations with primary and secondary antibodies were carried
out in 3% skim milk TBST at room temperature for 1 h.
SuperSignal West Pico chemiluminescent substrate was used for
detection of HRP. Images were captured with a Kodak Image
Station 4000R (Molecular Imaging system Carestream Health,
INC.), and Carestream Molecular Imaging Software, Network
Edition v. 5.0.5.31 was used for analysis of pixel intensity.
Chemical inhibition of SpeB during in vitro biofilm
formation
To inhibit SpeB in static biofilms, 100 mM of the irreversible
cysteine protease inhibitor L-trans-Epoxysuccinyl-leucylamido(4-
guanidino)butane (E64) (Sigma) was included at the time of
seeding and plates were incubated for 24 h at 37uC, 5% CO2.C V
staining for bacterial adherence was performed as described
above.
Murine subcutaneous infections
Studies were approved by the Animal Care and Use Committee
of Wake Forest University Health Sciences. Murine subcutaneous
infections were performed as previously described [42]. Logarith-
mic cultures were washed 3 times in 16 DPBS before infection.
Initial CFU of the infectious dose was confirmed by serial dilutions
plated onto THY agar plates. Five-week-old, outbred, immuno-
competent, hairless female Crl:SKH1-hrBR mice (Charles River)
received subcutaneous injections of ,2.0610
8 CFU (0.1 ml) of
either MGAS315, MGAS315Dsrv, RGAS053 or RGAS053Dsrv at
the base of the neck (n=10/strain). Mice that received E64
(Sigma) treatment were given ,2.0610
8 CFU MGAS5005Dsrv
resuspended in 333 mM E64-DPBS (0.1 ml) at the time of
infection, as well as daily treatments of 333 mM E64-DPBS
(0.1 ml) injected at the site of infection beginning 24 hours post
infection (n=3/strain). Area of the lesion formed at the site of
infection was measured daily using a caliper. The weight of each
mouse was recorded daily for up to 8 days following infection, at
which point the mice were euthanized and tissue at the site of
infection was excised. At 1, 3 and 8 dpi, a random subset of lesions
(n=3/strain) were excised and homogenized to enumerate the
bacterial load (CFU/g) as previously described [42]. Tissue
samples were also fixed for paraffin embedding or snap frozen
in liquid nitrogen and stored at 280uC.
Microscopic analysis of excised tissue
Tissue samples were excised and fixed at 8 dpi as previously
described (n=3/strain) [42]. Briefly, samples were fixed with fresh
1% paraformaldehyde for 24 hours at 4uC, stored in 70% ethanol
at room temperature, and paraffin embedded for sectioning.
Taylor’s Brown-Brenn modified Gram-stain was used for Gram-
staining tissue sections. A Nikon Eclipse TE300 Light Microscope
(Nikon) was used to examine microcolony formation in Gram-
stained sections, QImaging Retiga-EXi camera (AES) was used to
capture images, and ImageJ version 1.43 software (rsbweb.nih.gov)
was used to store images.
Statistics
Significance was determined by using Student’s unpaired t-tests
and all p values are two tailed at a 95% confidence interval.
Analyses were performed using GraphPad Prism, version 5
(GraphPad Software, San Diego, CA).
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